Fig. 2.

Effect of EBP1 expression on lapatinib sensitivity in androgen-containing and androgen-depleted conditions. Cells were treated with lapatinib at the indicated concentrations in either androgen-containing (+And, left panel) or androgen-depleted (−And, right panel) media. Cell number was determined 5 days later as described in the “Materials and Methods” section. Each data point represents the Mean ± SD of 6 wells. Similar results were observed in two independent experiments. A16 and C13 cells are LNCaP derivatives in which EBP1 is expressed (A16) or silenced (C13). The EBP1 overexpressing (E) and vector control (V) C4-2B and C81 cells are indicated. Insets indicate EBP1 expression as determined by Western blotting using EBP1 (LNCaP and C81) or GFP (C4-2B) and GAPDH antibodies as indicated. *p < 0.05; **p < 0.01 EBP1-silenced or EBP1-transfected cells versus vector control cells